<div id="readability-page-1"><p>Wells Fargo analyst Derek Archila maintained a Buy rating on Ventyx Biosciences today and set a price target of $14.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Archila is a 5-star analyst with an average return of <span>17.1%</span> and a 55.44% success rate. Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Soleno Therapeutics, and Kyverna Therapeutics, Inc..</p> <p>Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $13.67.</p></div>

VTYX

<p>Wells Fargo analyst Derek Archila maintained a Buy rating on Ventyx Biosciences, setting a price target of $14.00. Archila, a 5-star analyst with a 17.1% average return, focuses on the Healthcare sector. The analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $13.67.</p>

Wells Fargo Remains a Buy on Ventyx Biosciences (VTYX)